HCA Health Inc vs Medpace Holdings Inc — how do they compare? HCA Health Inc trades at $410 (market cap $89.08B), while Medpace Holdings Inc trades at $607 (market cap $16.90B). The key difference: HCA Health Inc is far larger — about 5.3× Medpace Holdings Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| HCA | MEDP | |
|---|---|---|
Market Cap | $89.08B | $16.90B |
Sector | Health | Technology |
52-Week High | $545.13 | $620.59 |
52-Week Low | $361.32 | $393.42 |
Enterprise Value | $139.62B | $16.52B |
Dividend Yield | 0.76% | — |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →